Celltrion's ustekinumab biosimilar, CTP-43, is currently in pre-registration for the treatment of psoriatic arthritis. This development signals a significant step towards market availability, supported by GlobalData's analysis indicating a 100% phase transition success rate (PTSR) for drugs in pre-registration for this indication.
Mechanism of Action and Clinical Development
CTP-43 is a human monoclonal antibody administered subcutaneously. It functions as an immunosuppressant by targeting the interleukin 12 subunit beta and interleukin 23 subunit alpha. This mechanism is crucial in managing the inflammatory response associated with psoriatic arthritis, plaque psoriasis, ulcerative colitis, and Crohn's disease, all of which are potential indications for CTP-43.
Celltrion's Expertise in Biosimilars
Celltrion, a biopharmaceutical company based in Incheon, South Korea, specializes in the research, development, and manufacturing of biosimilars and novel biopharmaceuticals. Their portfolio includes monoclonal antibodies for treating rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, Crohn’s disease, psoriatic arthritis, and psoriasis. The company employs bioengineering and mammalian cell-culture technology to develop its drugs.
Market Potential and GlobalData Analysis
GlobalData's assessment of CTP-43 includes drug-specific PTSR and Likelihood of Approval (LoA) scores compared to indication benchmarks. The pre-registration status for psoriatic arthritis suggests a promising outlook for CTP-43, given the historical success rate of drugs at this stage. Ustekinumab (Steqeyma) is already approved for the treatment of Crohn's disease, plaque psoriasis, psoriatic arthritis and ulcerative colitis.
